Ligand and agenus enter into $100 million royalty financing agreement

Jupiter, fla. and lexington, mass.--(business wire)--ligand pharmaceuticals incorporated (nasdaq: lgnd) and agenus inc. (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support agenus' key development initiatives in the ongoing bot/bal clinical development program, including its planned confirmatory phase 3 trial in its lead indication of patients with.
AGEN Ratings Summary
AGEN Quant Ranking